Immutep (NASDAQ:IMMP) Price Target Raised to $7.00

Immutep (NASDAQ:IMMP) had its target price lifted by Robert W. Baird from $6.00 to $7.00 in a research report released on Friday morning,Benzinga reports. The firm currently has an outperform rating on the biotechnology company’s stock.

Immutep Trading Down 1.9 %

Shares of IMMP opened at $2.05 on Friday. Immutep has a 1 year low of $1.58 and a 1 year high of $3.34. The company has a quick ratio of 18.25, a current ratio of 18.25 and a debt-to-equity ratio of 0.01. The stock has a 50 day simple moving average of $2.10 and a two-hundred day simple moving average of $2.32.

Institutional Trading of Immutep

Several hedge funds have recently added to or reduced their stakes in IMMP. XTX Topco Ltd bought a new stake in shares of Immutep in the 2nd quarter valued at about $26,000. BNP Paribas Financial Markets lifted its position in Immutep by 15.4% in the first quarter. BNP Paribas Financial Markets now owns 35,300 shares of the biotechnology company’s stock valued at $82,000 after purchasing an additional 4,700 shares during the last quarter. Virtu Financial LLC lifted its position in Immutep by 269.4% in the first quarter. Virtu Financial LLC now owns 45,062 shares of the biotechnology company’s stock valued at $105,000 after purchasing an additional 32,864 shares during the last quarter. XY Capital Ltd purchased a new stake in shares of Immutep during the second quarter valued at approximately $105,000. Finally, Meridian Wealth Management LLC grew its holdings in shares of Immutep by 4.5% in the third quarter. Meridian Wealth Management LLC now owns 398,450 shares of the biotechnology company’s stock worth $881,000 after purchasing an additional 17,250 shares during the last quarter. 2.32% of the stock is owned by institutional investors.

Immutep Company Profile

Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system.